Deputy Chair, Jørgen Bardenfleth has reported that he has bought 32,000 shares, which brings his total shareholding up to 457,629 shares.
Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||
| a) | Name | Jørgen Bardenfleth | ||
| 2. | Reason for the notification | |||
| a) | Position/status | Board member | ||
| b) | Initial notifica- tion/Amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Scandion Oncology A/S | ||
| b) | LEI | 549300MPWDMQ5LZEGD09 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instru- mentIdentification code | SharesISIN code for shares: DK0061031895 | ||
| b) | Nature of the transaction | Purchase | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| 8.75 SEK | 32,000 | |||
| d) | Aggregated information
|
|||
| e) | Date of the transaction | 05.08.2022 | ||
| f) | Place of the transaction | First North GM Sweden | ||
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
Email: ir@scandiononcology.com
The information was provided by the contact person above for publication on August 8, 2022, at 17.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.